Display options
Cite
Bánvölgyi A, Lőrincz K, Kiss N, et al. Efficiency of long-term high-dose intravenous ascorbic acid therapy in locally advanced basal cell carcinoma - a pilot study. Postepy Dermatol Alergol. 2019;37(4):548-558doi: 10.5114/ada.2019.83027.
Bánvölgyi, A., Lőrincz, K., Kiss, N., Avci, P., Fésűs, L., Szipőcs, R., Krenács, T., Gyöngyösi, N., Wikonkál, N., Kárpáti, S., & Németh, K. (2020). Efficiency of long-term high-dose intravenous ascorbic acid therapy in locally advanced basal cell carcinoma - a pilot study. Postepy dermatologii i alergologii, 37(4), 548-558. https://doi.org/10.5114/ada.2019.83027
Bánvölgyi, András, et al. "Efficiency of long-term high-dose intravenous ascorbic acid therapy in locally advanced basal cell carcinoma - a pilot study." Postepy dermatologii i alergologii vol. 37,4 (2020): 548-558. doi: https://doi.org/10.5114/ada.2019.83027
Bánvölgyi A, Lőrincz K, Kiss N, Avci P, Fésűs L, Szipőcs R, Krenács T, Gyöngyösi N, Wikonkál N, Kárpáti S, Németh K. Efficiency of long-term high-dose intravenous ascorbic acid therapy in locally advanced basal cell carcinoma - a pilot study. Postepy Dermatol Alergol. 2020 Aug;37(4):548-558. doi: 10.5114/ada.2019.83027. Epub 2019 Feb 26. PMID: 32994778; PMCID: PMC7507164.
Copy Download .nbib Format: NLM
Share it on

Postepy Dermatol Alergol. 2020 Aug;37(4):548-558. doi: 10.5114/ada.2019.83027. Epub 2019 Feb 26.

Efficiency of long-term high-dose intravenous ascorbic acid therapy in locally advanced basal cell carcinoma - a pilot study.

Postepy dermatologii i alergologii

András Bánvölgyi, Kende Lőrincz, Norbert Kiss, Pinar Avci, Luca Fésűs, Róbert Szipőcs, Tibor Krenács, Nóra Gyöngyösi, Norbert Wikonkál, Sarolta Kárpáti, Krisztián Németh

Affiliations

  1. Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
  2. Wigner RCP, Institute for Solid State Physics and Optics, Budapest, Hungary.
  3. R&D Ultrafast Lasers Ltd; Wigner RCP, Institute for Solid State Physics and Optics, Budapest, Hungary.
  4. 1 Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

PMID: 32994778 PMCID: PMC7507164 DOI: 10.5114/ada.2019.83027

Abstract

INTRODUCTION: The anti-cancer properties of high-dose intravenous ascorbic acid have been demonstrated in various malignancies. In our recent study, we tested topically applied ascorbic acid to treat basal cell carcinoma (BCC), and achieved a good clinical response.

AIM: Based on these results, we decided to examine the efficacy and tolerability of high-dose intravenous ascorbic acid (IVA) for locally advanced BCC.

MATERIAL AND METHODS: In this pilot study, patients diagnosed with locally advanced BCC who were not amenable to radiation, surgical or local therapy (no other treatment option was available at the time) received intravenous ascorbic acid (1-1.8 g/kg), in an outpatient setting, 1-3 times per week for a mean duration of 42 ±23.6 weeks. This therapy was generally well tolerated.

RESULTS: Among 4 patients who had a total of 165 (mean: 41 ±51, range: 1-114) skin lesions, 3 patients achieved stable disease and one had progressive disease. There was substantial variability in individual tumor response to therapy. With the aid of two-photon microscopy and second harmonic generation imaging techniques, alterations in collagen structure were observed between tumor nests during IVA therapy.

CONCLUSIONS: Our results suggest that IVA is well tolerated in a small group of patients with extensive BCCs. However, in the era of smoothened (Smo) receptor inhibitors, it may only be considered as an adjuvant therapy in treatment-resistant cases.

Copyright: © 2019 Termedia Sp. z o. o.

Keywords: ascorbic acid; basal cell carcinoma; vitamin C

Conflict of interest statement

Dr. Szipőcs holds shares in R&D Ultrafast Lasers Ltd. The remaining authors declare no conflict of interest.

References

  1. Curr Dermatol Rep. 2014 Feb 9;3:40-45 - PubMed
  2. Future Oncol. 2018 Mar;14(6):515-525 - PubMed
  3. Science. 2015 Dec 11;350(6266):1391-6 - PubMed
  4. Biochim Biophys Acta. 2013 Dec;1836(2):245-54 - PubMed
  5. Int J Cancer. 2007 Mar 15;120(6):1192-7 - PubMed
  6. Int J Clin Exp Pathol. 2014 Aug 15;7(9):5855-63 - PubMed
  7. Pathol Oncol Res. 2019 Jul;25(3):1015-1021 - PubMed
  8. Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2048-57 - PubMed
  9. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  10. Pathol Res Pract. 2003;199(11):705-12 - PubMed
  11. Cell. 2008 Sep 5;134(5):703-7 - PubMed
  12. Biomed Opt Express. 2016 Oct 07;7(11):4480-4489 - PubMed
  13. J Am Acad Dermatol. 2016 Jul;75(1):212-3 - PubMed
  14. Biochim Biophys Acta. 2012 Dec;1826(2):443-57 - PubMed
  15. Eur J Dermatol. 2011 Jul-Aug;21(4):608-9 - PubMed
  16. J Cutan Pathol. 2002 Nov;29(10):585-9 - PubMed
  17. Indian J Dermatol. 2017 Jan-Feb;62(1):103-105 - PubMed
  18. J Clin Invest. 1986 Apr;77(4):1312-20 - PubMed
  19. Nature. 1999 May 6;399(6731):70-5 - PubMed
  20. Ann Oncol. 2008 Nov;19(11):1969-74 - PubMed
  21. Anticancer Drugs. 2012 Apr;23(4):437-44 - PubMed
  22. Integr Cancer Ther. 2014 Jul;13(4):280-300 - PubMed
  23. N Engl J Med. 2012 Jun 7;366(23):2171-9 - PubMed
  24. Am J Med Genet A. 2011 Sep;155A(9):2091-7 - PubMed
  25. Nat Commun. 2013;4:1881 - PubMed
  26. Cancer Cell. 2015 Mar 9;27(3):315-6 - PubMed
  27. JAMA Dermatol. 2015 Oct;151(10):1068-74 - PubMed
  28. J Cancer Res Clin Oncol. 1994;120(7):415-21 - PubMed
  29. Pathol Oncol Res. 2012 Jul;18(3):721-8 - PubMed
  30. J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8 - PubMed
  31. Adv Exp Med Biol. 2008;624:89-103 - PubMed
  32. Healthcare (Basel). 2013 Oct 17;1(1):64-83 - PubMed
  33. Arch Dermatol Res. 2014 Aug;306(6):539-44 - PubMed
  34. Hum Pathol. 1996 Jul;27(7):695-700 - PubMed
  35. Photodiagnosis Photodyn Ther. 2018 Jun;22:7-13 - PubMed
  36. Nature. 1993 Jul 1;364(6432):79-82 - PubMed
  37. J Biol Chem. 1999 Jul 9;274(28):19792-8 - PubMed
  38. Lancet Oncol. 2015 Jun;16(6):716-28 - PubMed
  39. J Biol Chem. 2005 Feb 11;280(6):4254-63 - PubMed
  40. Am J Pathol. 2011 Mar;178(3):1221-32 - PubMed
  41. Future Oncol. 2014 May;10(6):927-36 - PubMed
  42. Ann Biomed Eng. 2012 Feb;40(2):277-91 - PubMed
  43. J Cell Physiol. 2005 Mar;202(3):654-62 - PubMed
  44. Clin Exp Dermatol. 2018 Jul;43(5):559-565 - PubMed
  45. Cancer Chemother Pharmacol. 2013 Jul;72(1):139-46 - PubMed
  46. P R Health Sci J. 2005 Dec;24(4):269-76 - PubMed
  47. Science. 1956 Feb 24;123(3191):309-14 - PubMed

Publication Types